You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Mass. Movers

ArQule’s lead drug faces hurdle on dosing

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Joanne Rathe/Globe Staff/File 2007

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Woburn-based ArQule Inc. and its development partner, Daiichi Sankyo Co., said that they will implement a lower dose of their treatment for hard-to-treat cases of liver cancer, Dow Jones reported. The change was recommended by a Food and Drug Administration panel following increased incidences of low white blood cell counts. The announcement is the latest hurdle for tivantinib, ArQule’s lead product candidate.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week